Sun Pharma's Utreglutide Shows Promising Results in Obesity and MASLD Treatment

Sun Pharmaceutical Industries Ltd. presented two posters at the ObesityWeek® 2025 Scientific Sessions. The first poster presented data from a subgroup of Phase 1b/2a Study of utreglutide (GLO034) in overweight and obese individuals and Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD). The subgroup comprised individuals with Class III Obesity and MASLD. Thirteen weeks of utreglutide dosing in individuals with obesity and MASLD showed body weight and waist circumference reduction, improved cardio-metabolic markers, significant liver fat loss in 31% of subjects, and reduced urate levels. The drug was well tolerated. The second poster presented data from a 10-week safety and efficacy study administering utreglutide (GLO034) in individuals with obesity. Once-weekly utreglutide dosing over ten weeks in individuals with overweight and obesity led to 6.8% body weight loss, about 10% TC and LDL reduction, 16.3% ApoB drop, and significant improvements in inflammatory markers, liver enzymes, and fatty liver index.